STERICYCLE SRCL - WKN 902518 - Entsorger von Krankenhausmüll - 500 Beiträge pro Seite

[spaceistheplace]

Hallo,

Stericycle entsorgt Krankenhausabfälle.
Nach wochenlangem Hin- und Herüberlegen wegen des kontinuierlich steigenden Charts habe ich den Entschluss gefasst, doch in SRCL einzusteigen. Scheinbar gibts da kaum eine Korrektur. Ich habe gestern ne kleine Pos. gekauft. Mein Bauch sagte was anderes wegen der hohen Bewertung. Jedoch hat vor einigen tagen der CEO noch mal kräftig zugelangt mit Käufen, heute kommen Quartalszahlen nachbörslich. Das geht auch gegen meine gewöhnliche Vorgehensweise, Aktien vor den Zahlen zu kaufen, denn das ist oft echt reine Spekulation, da die Ausschläge bei kleineren Werten oft erheblich sind.
Also ein absolut prozyklischer Kauf, wie es eigentlich nicht mein Stil ist.

Die Branche in der SRCL tätig sind, ist so was von unzyklisch, dass es mir so richtig in den Kram passt. Das einzige Manko ist die hohe Bewertung und dass sie z.T. durch Übernahmen wachsen, was mal mit Problemen verbunden sein kann. Jedoch waren die bisherigen Übernahmen immer rel. kleine Firmen und keine großen Batzen, die meist mehr Schwierigkeiten bereiten.
Unten im Chart sieht man, wie stabil der Wert schon seit Jahren ist, der Millenniumscrash ist nicht in einer Spur zu sehen...echt erstaunlich...im Gegenteil, diese 3 Jahre waren ja mit die besten in der noch rel. kurzen Börsengeschichte.
Das ist z.B. an der US-Börse oft zu bemerken. Es wird bei kleineren Unternehmen mehr auf die Unternehmensentwicklung geschaut als auf das allg. Marktverhalten im Gegensatz zu Deutschland. Da möchte ich nicht wissen, wie bei unserem Nachgeäffe der US-Börsen der Chart aussehen würde, sollte SRCL in D. notiert sein...

Jetzt würde mich natürlich interessieren, ob hier noch jemand anderes die Aktie kennt bzw. investiert ist. Vielleicht kommt ja ein kleiner Austausch zu Stande.

Gruss space

Hier der langfristchart seit Börsengang in 1997:

[spaceistheplace]

Hier die aktuellen Quartalszahlen, im rahme der Erwartungen, wenn ich das richtig sehe...
Stericycle, Inc. Reports Results for Third Quarter 2007

Last Update: 4:03 PM ET Oct 25, 2007
PrintPrint EmailE-mail Subscribe to RSSSubscribe to RSS DisableDisable Live Quotes
LAKE FOREST, Ill., Oct 25, 2007 (BUSINESS WIRE) -- Stericycle, Inc. today reported financial results for the third quarter of 2007.
THIRD QUARTER AND YEAR-TO-DATE RESULTS
Revenues for the quarter ended September 30, 2007 were $237.3 million, up 16.8% from $203.3 million in the third quarter of 2006. Acquisitions less than 12 months old contributed $12.3 million to the $34.0 million revenue growth in the third quarter of 2007. Gross profit was $106.8 million, up 18.0% from $90.5 million in the third quarter last year. Gross profit as a percent of revenues was 45.0% versus 44.5% in the third quarter of 2006.
Net income for the third quarter of 2007 was $32.9 million or $0.37 per diluted share compared with net income of $27.5 million or $0.30 per diluted share for the third quarter of 2006. During the second quarter of 2007 we completed a 2-for-1 stock split. All historical per share numbers have been adjusted for the split.
For the nine months ended September 30, 2007, revenues increased to $681.2 million, up 17.3% from $580.9 million in the same period a year ago. Gross profit was $305.6 million, up 19.0% from $256.8 million in the same period a year ago. Gross profit as a percent of revenues was 44.9% versus 44.2% in the same period in 2006. Earnings per diluted share increased 24.3% to $1.05 from $0.84 per diluted share in the same period a year ago.
Cash flow from operations was $128.1 million for the first nine months of 2007. Cash flow and increased loan balances funded $95.2 million in stock repurchases, $79.0 million in acquisitions and international investments and $37.6 million in capital spending.
For more information about Stericycle, please visit our website at www.stericycle.com.
Safe Harbor Statement: Statements in this press release may contain forward-looking statements that involve risks and uncertainties, some of which are beyond our control (for example, general economic conditions). Our actual results could differ significantly from the results described in the forward-looking statements. Factors that could cause such differences include difficulties in completing the integration of acquired businesses, changes in governmental regulation of medical waste collection and treatment, and increases in transportation and other operating costs, as well as the various other factors described in our filings with the U.S. Securities and Exchange Commission. As a result, past financial performance should not be considered a reliable indicator of future performance, and investors should not use historical trends to anticipate future results or trends. We make no commitment to disclose any subsequent revisions to forward-looking statements.
Conference call to be held October 25, 2007 at 4:00 p.m. Central time - Dial 866-814-8448 at least 5 minutes before start time. If you are unable to participate on the call, a replay will be available through November 22nd by dialing 888-266-2081, access code 1137831. To hear a simulcast of the call over the internet, or to access an audio archive of the call, go to the Investor Relations page on Stericycle's website at www.stericycle.com.

STERICYCLE, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)


September 30, December 31,
2007 2006
------------- -------------
(unaudited) (audited)
ASSETS
Current assets:
Cash and cash equivalents $ 7,703 $ 13,492
Short-term investments 812 2,548
Accounts receivable, less allowance for
doubtful accounts of $5,985 in 2007 and
$5,411 in 2006 154,763 130,354
Deferred tax asset 14,431 16,072
Asset group held for sale - 33,674
Other current assets 26,514 22,462
------------- -------------
Total current assets 204,223 218,602
Property, plant and equipment, net 185,327 156,953
Other assets:
Goodwill 920,848 813,973
Intangible assets, less accumulated
amortization of $14,068 in 2007 and
$11,454 in 2006 143,664 115,879
Other 20,235 22,499
------------- -------------
Total other assets 1,084,747 952,351
------------- -------------
Total assets $ 1,474,297 $ 1,327,906
============= =============

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $ 16,440 $ 22,681
Accounts payable 35,597 25,033
Accrued liabilities 75,064 75,434
Deferred revenue 13,507 11,662
Liability group held for sale - 7,221
------------- -------------
Total current liabilities 140,608 142,031
------------- -------------
Long-term debt, net of current portion 545,146 443,115
Deferred income taxes 119,009 105,521
Other liabilities 13,468 12,158
Common shareholders' equity:
Common stock (par value $0.01 per share,
120,000,000 shares authorized,
86,971,032 issued and outstanding in
2007, 88,503,930 issued and outstanding
in 2006) 870 443
Additional paid in capital 180,042 252,568
Accumulated other comprehensive income 14,033 5,229
Retained earnings 461,121 366,841
------------- -------------
Total shareholders' equity 656,066 625,081
------------- -------------
Total liabilities and
shareholders' equity $ 1,474,297 $ 1,327,906
============= =============


Total debt to capitalization percentage
ratio 46.1% 42.7%
Calculation of total debt to
capitalization percentage ratio:
Total debt $ 561,586 $ 465,796
Shareholders' equity 656,066 625,081
------------- -------------
Capitalization $ 1,217,652 $ 1,090,877



STERICYCLE, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)

[spaceistheplace]

Hier das Transscript der earnings call gestern:


Stericycle Inc. Q3 2007 Earnings Call Transcript
posted on: October 26, 2007

Stericycle Inc. (SRCL)
Q3 2007 Earnings Call
October 25, 2007, 5:00 PM ET

Executives

Elizabeth L. Brandel - VP, Finance
Frank J.M. Ten Brink - EVP, CFO, and Chief Administrative Officer
Richard T. Kogler - EVP and COO
Mark C. Miller - President and CEO

Analysts

Scott Schneeberger - CIBC World Markets
David Manthey - Robert W. Baird
Ryan Daniels - William Blair & Company
Jonathan Ellis - Merrill Lynch
Unidentified Analyst - Citigroup
Scott Levine - JP Morgan
Greg Halter - Great Lakes Review
Unidentified Analyst - Banc of America
Cliff Walsh - Julius Baer

Presentation


Operator

Good day, ladies and gentlemen, and welcome to your Stericycle Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions]. As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Ms. Liz Brandel, Vice President of Finance. Ma'am, you may begin.

Elizabeth L. Brandel - Vice President, Finance

Thank you very much and welcome to Stericycle third quarter conference call. On today’s call will be Frank ten Brink, Chief Financial Officer; Rich Kogler, Chief operating Officer; and Mark Miller, Chief Executive Officer.

I will now read the Safe Harbor statement. Statements by Stericycle in this conference call that are not strictly historical are forward-looking. Forward-looking statements involve known and unknown risks and should be viewed with caution as just described in the Company’s Form 10-K, 10-Q, as well as other filings with the SEC could affect the Company’s actual results and could cause the Company’s actual result to differ materially from expected results. The Company makes no commitment to disclose any revisions to forward-looking statements or any facts, events, or circumstances after this date that may bear upon forward-looking statements.

I will now pass the call to Frank.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Thanks Liz.

The results for the third quarter are as follows. Revenues grew $34.1 million to $237.3 million, up 16.8% from $203.3 million in Q3 of ’06. Internal growth for the Company was $22.9 million or 11.6%, which is adjusted for the divested to some assets of STG and foreign exchange. Domestic growth was 11.6% and international growth adjusted for exchange and divestiture was also 11.6%. Domestic growth consisted of SQ up over 10%, LQ up 6% and returns management growth of $5.6 million.

Gross profit was $106.8 million or 45% of revenues, and SG&A expense was $44.6 million or 18.8% of revenues. Operating income was $61.9 million or 26.1% of revenues. Net interest expense was $8.6 million for $7.3 million in ’06 due to increase borrowings related to acquisitions and repurchases of shares completed in the quarter. Net income was $22.9 million or $0.37 per share.

At the end of the quarter, the revolver borrowings were approximately $456 million and the unused portion of our revolver is approximately $324 million. In August, we increased our revolver facility from $650 million to $850 million, and extended the maturity date to August 2012.

We repurchased approximately 757,000 shares of common stock on the open market in an amount of approximately $36.5 million. Since the beginning of the repurchase program, on a split adjusted basis, we purchased the total over 7.5 million shares. We still have authorization to purchase an additional 3.7 million shares. Our CapEx in the quarter was $14.5 million. The DSO in the quarter was 59 days, and the cash provided from operation was 57.7 million.

Now, a brief recap of the nine months numbers. For the nine months ended September 30 ’07, revenues increase to $681.2 million, an increase of 17.3% from the same period a year ago. Gross profit as a percentage of revenue was 44.9% for the nine months ended ’07 versus 44.2% for the same period, the prior year. Earnings per share increased to $1.5 from $0.84 per diluted share in the same period a year ago, and that’s split adjusted, and the cash flow from operations was $128.1 million for the first nine months of ’07.

I will now turn it over to Rich.

Richard T. Kogler - Executive Vice President and Chief Operating Officer

Thanks Frank. We want to thank each member of our worldwide team for their solid performance and continued commitment to our customers and shareholders. We enjoyed strong sales growth in all of our business segments in the quarter.

The SQG growth was primarily driven by SteriSafe with two-thirds of new SteriSafe customers choosing select and preferred. SteriSafe contributed approximately 53% of total small customer revenues. LQG sales growth was driven by the continued option of our Bio Systems offering and new LQG and Med waste contracts.

In summary, we ended Q3 with approximately 384,300 accounts, of which approximately 374,900 were small and the remainder large.

I will turn it over to Mark.

Mark C. Miller - President and Chief Executive Officer

Thanks Rich. I would now like to provide insight on our current outlook for the remainder of 2007 and provide a preliminary guidance for 2008. Please keep in mind that these are forward-looking statements.

During the third quarter, we completed two domestic acquisitions, and in addition in early October, we completed one international acquisition. The incremental revenue impact in 2007 for these latest acquisitions would be approximately $8.6 million, of which $2.2 million was in the third quarter.

The annualized revenues of these three acquisitions is approximately $26 million. Keeping these items in mind, we believe that analysts may fine tune our 2007 models to reflect revenues between $917 million and $923 million, and estimates for EPS of $1.41 to $1.42.

Now, I would like to provide a preliminary outlook for 2008, but please keep in mind that a preliminary guidance does not include future acquisitions or divestitures. We believe that analysts’ EPS estimates will be in the range of $1.64 to $1.68, which we are comfortable with. We believe that analysts’ estimates of revenue for 2007 would be in the range of approximately $995 million to $1.015 billion depending upon assumptions of growth in foreign exchange rates. We believe analysts will have estimates for net income between $147 million and $150 million, depending on their assumptions of margin improvement and interest expense. And analysts will have estimates for free cash flow between $140 million and $145 million, with our CapEx anticipated between $45 and $55 million.

In closing, we are very excited about the tremendous growth opportunities in 2008 and beyond.

We thank you for you time and operator will now switch over to Q&A.

Question and Answer

Operator

Thank you, sir. [Operator Instructions].

Our first question comes from Scott Schneeberger from CIBC World Markets.

Scott Schneeberger - CIBC World Markets

Hey, good afternoon, guys. How are you?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Good afternoon.

Scott Schneeberger - CIBC World Markets

I guess I would like to just start out just talking about recalls. I missed I think, Frank, you had said was that the returns on recalls growth, I had missed the number. Could you please share that again?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

It was $5.6 million over last year from a growth point of view. And in total, it was $22.3 million

Scott Schneeberger - CIBC World Markets

Okay. Thank you. Staying on that topic the… that’s something you had a lot of success within the second quarter and obviously an exciting growth business for you. Could you just speak a little bit, I guess to… is that an industry that’s in rapid growth, I mean, we see headlines frequently about consumer products being recalled. Is it just what we are seeing in the news that leads to believe that that’s growing rapidly? Or are there two signs we are seeing that you just speak to that I will appreciate it.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Well, Scott, I think from my prospective, not only we had a very solid year from the big recall activity that we are seeing. But our sense that there is a growing awareness of the core issue, because it’s happening beyond just the classic space of pharmaceutical and over the counter products. You see it happening and in durable products, you see it happening in consumer products of a variety. And so, our sense is that there’s growing awareness and pressure and that’s really for us one of the keys is as we keep building the awareness of our capabilities and also expanding what we can offer to our customers really helping our growth potential.

Scott Schneeberger - CIBC World Markets

All right. Thanks. That’s helpful. The… I guess, shifting gears a little bit, the… actually I will stay on that, for recalls, obviously, a lumpy business and if that grows as part… as one of your segments, do you envision breaking out returns in recalls going forward, just so, we are able… we appreciate the ’08 guidance, but just so we are able to breakout our models and consider the lumpiness factor.

Mark C. Miller - President and Chief Executive Officer

Yes, I think for us it’s though to segment or separate because often we may have an agreement with the customer that may include services enhance and encompass the returns management, we have it now capabilities for coupon and rebate management. So, new additional services or the efficiency checks and affectivity checks and retrieval capabilities, often they get wrapped together. So, it’s very, very tough to distinguish it because it leverages same structures, similar sales force, execution and like. So, at this point, we don’t have an easy way to break that out.

Scott Schneeberger - CIBC World Markets

Okay. Understood, so we shouldn’t anticipate that… and any confusion. Okay. Now, shifting gears, is, Rich, in Bio Systems, could you talk about how many markets what’s rollout to what… what the plan is for further growth? Just kind of speaking of the footprint.

Richard T. Kogler - Executive Vice President and Chief Operating Officer

Yes, we been rolling out pretty steadily now. And I think we were at in terms of penetration in the U.S., is probably 25%, possibly 30% of our target accounts. Although, like a lot of our services as the word gets out there, we get interest from labs and other and other people, so that market kind of continues to expand. I think the other thing to consider is we haven’t begun to move into foreign markets. So, we have basically all the international platform that… this will be applicable to.

Scott Schneeberger - CIBC World Markets

Great. Sounds good. One kind of more the model housekeeping question. Your tax rate was 38% in the quarter, a little bit lower than I had anticipated. Is that a result of maybe some acquisition, maybe something international, or something else?

Richard T. Kogler - Executive Vice President and Chief Operating Officer

No, it’s really kind of little bit of a year-to-date, a just down sort of year-to-date number, which right now is at 38.45 versus 38.5 before. And so, I think, overall, we are going to be right into that bandwidth maybe for the next year guidance, 38.5 is probably good rate to use.

Scott Schneeberger - CIBC World Markets

Fair enough. And just as far as fourth quarter, something in the similar range in the 38 to 38.5.

Richard T. Kogler - Executive Vice President and Chief Operating Officer

Yes.

Scott Schneeberger - CIBC World Markets

Okay. Fair enough. Thanks for all the help out there.

Richard T. Kogler - Executive Vice President and Chief Operating Officer

Thank you.

Operator

Our next question comes from David Manthey from Robert W. Baird.

David Manthey - Robert W. Baird

Hi. Thank you very much. Could you discuss infection control and/or any new initiatives that might be out there for you? And as it relates to that specific initiative, is that primarily for hospitals, or is it some service that you can offer to small customer as well?

Mark C. Miller - President and Chief Executive Officer

Most of the activities that we have done in the infection control research and pilot phase are targeted towards the large quantity customers at this point. And they would have applicability in other segments, but right now most of our research is focused on the LQ space. Part of that as we think, over the coming years, the awareness factor and also coming on [ph] infection will increase as hospitals have to do more reporting and there is more visibility as to what’s happening in terms of hospital acquired infections.

David Manthey - Robert W. Baird

Okay. Thank you. And should we be concerned all about fuel cost or labor or any other cost that are impacting you at this time?

Richard T. Kogler - Executive Vice President and Chief Operating Officer

Fuel has been a challenged this year, but it’s been challenged in prior years. And although, our guidance right now that we gave you assumes that we are sort of that current fuel prices and energy prices. The good news is our team has been very good at seeking out efficiencies to offset cost, and more importantly, our contracts allow us to do fuel pass-throughs. So, we have done that I think pretty effectively to counter the higher energy cost.

David Manthey - Robert W. Baird

And finally maybe you could talk about pricing just in your core services, how does the competitive landscape look to you today? Is it… are the pricing pressures getting greater or last sort of the same?

Richard T. Kogler - Executive Vice President and Chief Operating Officer

I think more of the same. I mean it is competitive business and there are many competitors out there that we compete with in all of the markets that were in. And I guess, that being said, that we have obvious competed effectively and we haven’t seen our change in pricing.

David Manthey - Robert W. Baird

Thank you very much.

Operator

Our next question comes from Ryan Daniels from William Blair.

Ryan Daniels - William Blair & Company

Yes, good afternoon, guys. Couple of quick housekeeping questions upfront. Do you have on hand the number of new large quantity generator accounts and Bio Systems account during the quarter?

Richard T. Kogler - Executive Vice President and Chief Operating Officer

Yes, for the new Med waste contracts the large quantity was 57, and we have captured 75 new Bio Systems accounts.

Ryan Daniels - William Blair & Company

Okay. And the how about SteriSafe editions during the quarter, do you have that number?

Richard T. Kogler - Executive Vice President and Chief Operating Officer

SteriSafe right now stands at about 114,000 total accounts.

Ryan Daniels - William Blair & Company

Okay. And what percentage of those given the continued strength of signing up initially towards the more premium services, do you have of those 114 on premium?

Richard T. Kogler - Executive Vice President and Chief Operating Officer

Right now, we have… in the quarter, we had over two-thirds taking select and preferred. And year-to-date, we are over 21% on select and preferred. So, it’s new height for us.

Ryan Daniels - William Blair & Company

Okay. Great. And then, Frank, in the years guidance for 2008 or Mark, whoever wants to address this. Can you give us a feel for what's implicit in there from the returns and recall business I know this year you got it that towards $70 million number, where do you see that going, is part of your ’08 guidance?

Mark C. Miller - President and Chief Executive Officer

I think from our perspective when we gave the ranges on revenues, we take the underlying growth of that business is not 10% per annum. It’s hard to judge and peel out what the base line is. And the ranges we gave you was a $70 million to $85 million number for 2008.

Ryan Daniels - William Blair & Company

Okay.

Mark C. Miller - President and Chief Executive Officer

And there through process is there. So, we have had some pretty big recalls, which have been favorable effects in Q2 and Q3, not sure whether we will capture those same levels next year, and if we get bigger recalls, then the momentum continues. It could be better, but we wanted to build something in and we thought was at least in our current knowledge and ability to look forward the something that was in a reasonable bandwidth.

Ryan Daniels - William Blair & Company

Okay. Great. That’s helpful color. Two more quick ones and I will hop off. Just another one back on the fuel cost, I know the cost have been elevated for a couple of quarters now. I am just curious how quickly you can pass those through, I know it written in the contract, but is that something where… it’s fairly immediate or you are going back one month to two months in a year, just any explanation on how that works?

Richard T. Kogler - Executive Vice President and Chief Operating Officer

We can react fairly quickly, but I think if you just think about it from the standpoint of lag, there will be a some lag and that’s why in the past, we said that we are able to counter, but there could be as these fuel surcharges build into the revenue, there could be some margin impact… minimal, but you might see it.

Ryan Daniels - William Blair & Company

Okay. Great. And the last one, it looks like decent CapEx quarter kind of a run rate of $60 million, given the just under 15 you did this quarter. Was anything significant there on the returns or recall business or anything international that drove that to a little bit of an uptick in the quarter.

Richard T. Kogler - Executive Vice President and Chief Operating Officer

Yes, I think I am not sure about the comment of $60 million… that maybe the run rate, but remember the CapEx is kind of lumpy. We are still holding to our guidance around 5% of revenues based on the new revenues and mid 40’s will be our spend this year, because of acquisitions and because of strength of recall business, we make decisions to pull some projects forward because they had strong IR’s.

Ryan Daniels - William Blair & Company

Okay. Perfect. Thanks for the color. Thanks guys.

Operator

Our next question comes from Jonathan Ellis from Merrill Lynch.

Jonathan Ellis - -Merrill Lynch

Thanks good evening guys.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Good evening.

Jonathan Ellis - -Merrill Lynch

Wanted to just… in terms the ’08 guidance, I wanted to… try to get some clarification what assumptions you are making in terms of SQ or LQ growth?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

The SQ is about 8% to 10%. LQ internal growth about 5% to 7%, and you are looking at an international somewhere in 7% to 9%.

Jonathan Ellis - -Merrill Lynch

Okay. And it seems like the LQ growth is down just modestly from the range you provided previously.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

A little bit, I mean you also get with Bio as a percent of the total, but overall, I mean it’s still good revenues coming in.

Jonathan Ellis - -Merrill Lynch

Okay. And then on the international business, I am wondering could you talk a little bit about the organic growth in that business this quarter versus international or versus acquired?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Well, in the quarter, we had 11.6% in growth and that is adjusted for the divestiture that we did and for foreign exchange. Foreign exchange in the quarter aided, if you compare to last year, about $3 million to the revenues.

Jonathan Ellis - -Merrill Lynch

Okay. And is that figure also adjusted though for acquisitions?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Yes, it is.

Jonathan Ellis - -Merrill Lynch

Okay, so that’s a near organic number.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Yes.

Jonathan Ellis - -Merrill Lynch

And then also in terms of the company that you bought abroad, would you really tell us what country that was in?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

That was in Canada.

Jonathan Ellis - -Merrill Lynch

Okay.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

That’s the one, that again, closed early October. It was kind of in the Canadian press.

Jonathan Ellis - -Merrill Lynch

Yes.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

And we acquired from Brands and Brick [ph].

Jonathan Ellis - -Merrill Lynch

Great. I appreciate that. And then in terms of the STG integration, how far along are you at this point and when do you think you will be done, where the integration of that company?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Again, STG is… because of the size of it, takes longer and as we said before it would probably definitely still run into the first half of next year, both from a waste flow point of view and just the integration between the two.

Jonathan Ellis - -Merrill Lynch

Okay. And then just finally, on the topic of U.K. Can you talk about mix of SQ versus LQ right now?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

I think if you look, it’s about little over 20% that right now is in the SQ in Europe. And then when we talk U.K., we have always talked about Ireland and U.K. together.

Jonathan Ellis - -Merrill Lynch

Yes. Okay. And then just one final question relates to share repurchase. It looks like this year, repurchase is up there quite a bit. Could you talk a little bit what your assumptions are going into next year in terms of repurchases?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Again in our guidance we don’t presume repurchases. So, again, from a guidance, we don’t make those predictions. Again, we are opportunistic in our repurchases and if we see opportunities we will take advantage of them.

Jonathan Ellis - -Merrill Lynch

Okay. Great. Thanks, guys.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Thank you.

Operator

Our next question comes from Leon Young from Citigroup.

Unidentified Analyst - Citigroup

Hi, it’s actually Elena Cellura [ph] for Leon. Just getting back to the acquisitions. In the quarter there were two domestic acquisitions you made. Were they in the Med waste?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Yes, they were.

Unidentified Analyst - Citigroup

Okay. And how was the pipeline now? Has there been any change?

Mark C. Miller - President and Chief Executive Officer

No, we are still… despite doing all the deals, we are still over $50 million in the North America marketplace.

Unidentified Analyst - Citigroup

Okay. And also margins, gross margin in the quarter was a little bit shy versus what we had expected and also sort of versus what you guys have said in the past for 30 basis points to 40 basis points of improvement quarter-over-quarter. Are you still expecting that kind of growth--?

Mark C. Miller - President and Chief Executive Officer

If you look in the quarter, there’s really three factors. We obviously from a revenue point of view were ahead of the expectations and that was both through due to acquisitions, International, there was a half opening growth as a result of foreign exchange. Those are normally come in at lower margins. Returns was also had a little bit rather the recall related, which is lower margins, if you blend all that, you really are going to come again to round to 45% gross margin. And if you really look ahead, I mean anywhere 15 to 20 basis points quarter-over-quarter from the next year point of view, but on the base, if you take all that kind of mix factors out, we were probably about 35 basis points up versus the prior quarter

Unidentified Analyst - Citigroup

Okay. Great. Thank you.

Operator

Our next question comes from Scott Levine from JP Morgan.

Scott Levine - JP Morgan

Good Afternoon.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Good afternoon.

Scott Levine - JP Morgan

Regarding the SG&A you don’t give this final level of detail yet for 2008 but you guys have been stepping up the strategic spend this years. Any thought in terms of what the bias might be on the SG&A kind of going forward beyond this period is elevated strategic spend?

Mark C. Miller - President and Chief Executive Officer

I think the current outlook in our preliminary guidance would be a key. Our SG&A levels comparable the kind of where we are running right now throughout Q4 and 2008. there is sill several programs that are under review that. I think they have great IR’s that will maybe pull forward, but as we have seen in the past those who paid off nicely for us. We really accelerated the sales and marketing efforts and gotten the returns for. So, I think the most of the models depending on how you treat amortization and acquisition related costs, you are going to come in mid to high 18s.

Scott Levine - JP Morgan

Got it. And then turning to acquisitions one follow-up. Any change in multiples you seeing out there and/or do you see any limit potentially in the domestic marketplace and what you can do with traditional rollout type opportunities?

Mark C. Miller - President and Chief Executive Officer

No, again, on the deals that we closed and the one right after quarter multiples again, they are sixth and seventh on a synergized basis. So, very much in a range and on deals that are in the pipeline, no. we are, again, anticipating similar kind of picture.

Scott Levine - JP Morgan

One last one on recalls. Are you guys contemplating or thinking there's any real additional investment necessary for you guys to grow the business beyond the warehouses you have, the technology infrastructure or are we pretty much done the heavy lifting there?

Richard T. Kogler - Executive Vice President and Chief Operating Officer

I think we will continue to support the businesses with whatever CapEx mates they have. Again, it’s not huge CapEx, but I think for us really the drive on awareness on expansion and capabilities is why we are putting a lot of our SG&A and things right now. So, we are excited about the space, it will continues to be one that we believe we can get over time to north of 20% EBITDA margins and have a very unique set of tools for helping our customers, to help their customers.

Scott Levine - JP Morgan

Do you have a sense… one last following. Do you have a sense with regard to the mix I know you don’t breakout returns versus recall? But do you have a rough sense in terms of mix of returns versus recall? You ultimately expect to achiever or you not thinking about that way.

Richard T. Kogler - Executive Vice President and Chief Operating Officer

No, we don’t really price it and think about the business in that regard.

Scott Levine - JP Morgan

Very good. Thanks.

Operator

Our next question comes from Greg Halter from Great Lakes Review

Greg Halter - Great Lakes Review

Thank you for taking the time to answer the questions. Relative to share buyback with the stock prices 55 plus, just wondering your appetite I presume is still there to buy given what else you see out there. What is the highest price you have paid to-date for stock?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

We don’t give that specific detail. If you really look and recall of the last quarter, the average in the quarter at that point was about 48.22.

Greg Halter - Great Lakes Review

Okay. And fuel costs, fuel and energy costs I should represented what percentage of your sales in the quarter?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

It was about 5.7%.

Greg Halter - Great Lakes Review

Basically about the same as last couple of quarters.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Correct

Greg Halter - Great Lakes Review

Okay And any commentary that you could provide relative to the pending acquisition of MedSolutions would be helpful. I think they are voted November 7, if I have that correct?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

I think that’s correct, I know that correct sorry. It's a tuck-in. It is a good transaction for us. It will have some what we would consider public company add backs. We have good operating company saving because of the fact that it’s tuck-in. In a range of a normal multiple again from transaction that size, and again, from that point of view, we anticipated to close early November.

Greg Halter - Great Lakes Review

And you envision taking any of their own proprietary businesses throughout your whole infrastructure, I think they have sort of onsite device possibly.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Again, everything comes with transaction. It will be evaluated to make money and case-by-case basis, we will look at it.

Greg Halter - Great Lakes Review

All right. And I didn’t hear the debt to EBITDA, do you have that figure, I appreciate it.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

It’s 1.99.

Greg Halter - Great Lakes Review

And you are still comfortable going up to three times.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Yes.

Greg Halter - Great Lakes Review

All ready. Thank you very much.

Operator

Our next question will be from Robert Willoughby from Banc of America.

Unidentified Analyst - Banc of America

Hello guys, this is Jason Fruechtel [ph] sitting in for Robert Willoughby. I miss your debt to cap picked up a bit. Should we expect that to continue to increase in the near term or--?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Again because of the repos, you are going to get an environment where debt to cap is probably not as good a indicator, I mean the debt that you picked out for us is a far better indicator for leverage ability and leverage kind of too high or low. 2.0 for us, the 1.99 we feel it’s still on the conservative side. We are going to keep managing that, most likely we will be anywhere between one and a half, two and a half is a kind of normal bandwidth for us. Could we at times go a little lower to debt. Yes, depending on the transaction and historic if you look back our lowest has been about 1.2 so, no, we feel comfortable with it, I think debt to cap is probably not as good an indicator to use.

Unidentified Analyst - Banc of America

Okay, and just a question on your water management services that you provide. Could you discuss how many customers you had in the quarter and if you target a specific type of health care facility, I mean profit versus non-profit?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Yes, the water treatment program is still on pilot phase so there’s no material impact to the quarter or material numbers don’t enter our remaining ’07 or ’08 guidance so should we wall [ph] that out that would be upside but we are not anticipating anything at this point in time and our target base foe that type of service would be predominantly primary hospital market place or LQ market place so it would be applicable to nursing homes, essentially any place where you are going to have patients that are potentially immune compromised that are going to need cleaner water sources and water borne organisms.

Unidentified Analyst - Banc of America

Okay. Great, thanks.

Operator

Our next question comes from Cliff Walsh from Julius Baer.

Cliff Walsh - Julius Baer

Good afternoon.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Good afternoon.

Cliff Walsh - Julius Baer

Frank, you gave us a $50 million pipeline for North America. Is there an international number that you can share with us?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

We don’t disclose the international because it would be maybe too obvious as to what kind of transactions we would be looking at.

Cliff Walsh - Julius Baer

Okay. And in terms of recent acquisitions can you maybe comment on respective companies in terms of where they fit in terms of pricing, in the market we are talking about some of the lower priced competitors maybe that we can surprise improve over time in those markets?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

Again I think, simple thing is it’s post multiple 6 to 7 from a pricing point of view, it’s very much in our bandwidth. They are tuck ins and sort of good transactions for us.

Cliff Walsh - Julius Baer

I wasn’t talking about valuations, I was talking more specific pricing, customer pricing in the markets that where you are competing with these companies. Were they 10% below you in terms of price or 20% or maybe just comment on the ability to maybe raise the pricing in those small markets.

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

No, this market is so close together again that you will not see those kind of differences.

Cliff Walsh - Julius Baer

Okay. Great, thank you.

Operator

Our next question comes from Scott Schneeberger from CIBC World Markets.

Scott Schneeberger - CIBC World Markets

Hey guys, thanks for taking my call. Just a quick one. In this arbitration case going on in Australia and that has yet to be quantified as far as I am familiar. Can you provide enough date has that been quantified or are you still waiting on that. Any color on it?

Frank J.M. Ten Brink - Executive Vice President, Chief Financial Officer, and Chief Administrative Officer

No, it hasn’t been quantified yet. It’s our anticipation that there will probably be a pending Q4 kind of outcome probably in the latter part and… no. No quantification yet.

Scott Schneeberger - CIBC World Markets

Okay. Thanks so much. Appreciate it.

Operator

[Operator Instructions]. I am sure no further questions at this time sir.

Mark C. Miller - President and Chief Executive Officer

We thank everybody for your time and attention. 2008 is going to be a great year and we appreciate all your support. Have a great day.

Operator

Ladies and Gentlemen thank you for participating in today’s conference. This concludes our program for today. You may all disconnect and have a wonderful day.

[spaceistheplace]

na, mal gespannt, was die Nasdaq heute aus den zahlen macht:
EPS 1 cent über Erwartungen, der Umsatz etwas stärker (E: 227, Fakt 237)

Stericycle 3Q EPS 37 Cents Vs EPS 30 Cents

DOW JONES NEWSWIRES

Stericycle Inc.'s (SRCL) third-quarter net income rose 19% to $32.9 million, or 37 cents a share, from $27.5 million, or 30 cents a share, a year earlier.

The Lake Forest, Ill., waste management company's revenue increased 17% to $ 237.3 million from $203.3 million a year ago.

On average, analysts polled by Thomson Financial predicted third-quarter earnings of 36 cents a share and revenue of $227 million.

-Monica M. Clark; 201-938-5400; [e-mail]

[Pontiuspilatus]

na, mal gespannt, was die Nasdaq heute aus den zahlen macht:
EPS 1 cent über Erwartungen, der Umsatz etwas stärker

nicht schlecht sag ich

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.165.626 von Pontiuspilatus am 26.10.07 17:22:33

ja, die 4% sind mehr als ich gedacht habe, den so viel besser waren die Ergebnisse nicht als erwartet.

Hier, der satz von Pres. Miller ist vielleicht wichtig aus der telefonkonferenz:

Now, I would like to provide a preliminary outlook for 2008, but please keep in mind that a preliminary guidance does not include future acquisitions or divestitures. We believe that analysts’ EPS estimates will be in the range of $1.64 to $1.68, which we are comfortable with.

Die guidance der Analos für 2008 wird also klar bestätigt, jedoch ist dies ohne Übernahmen möglich. Im Quartalsbericht jetzt kommen aber auch Gewinnzuwächse durch jüngst geschehene Übernahmen dazu.
Hier aus dem Quartalsbericht:
Revenues for the quarter ended September 30, 2007 were $237.3 million, up 16.8% from $203.3 million in the third quarter of 2006. Acquisitions less than 12 months old contributed $12.3 million to the $34.0 million revenue growth in the third quarter of 2007.
Dieser ist nicht ohne, oder?

Und jetzt sagt mir einer, die übernehmen im nächsten jahr niemand...
Also da ist noch Luft nach oben in 2008. Vielleicht ist das sogar der Grund, dass es heute schön nach oben geht.

So, jetzt aber genug analysiert fürs erste.

Gruss und einen schönenAbend
space

[clearasil]

Antwort auf Beitrag Nr.: 32.168.336 von spaceistheplace am 26.10.07 20:24:34

Ich fand die Tatsache interessant, dass srcl in Sachen Produktumtausch aktiv ist. Gute Erweiterung des bestehenden Geschäfts. Ansonsten sieht hier alles gut aus.

gruß clearasil

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.234.851 von clearasil am 01.11.07 16:08:24

Ansonsten sieht hier alles gut aus.

und heute ersma....über 1% plus bei der Sch...Börse in den USA. da wirken die zahlen wohl immer noch nach...

Gruss space

[clearasil]

Antwort auf Beitrag Nr.: 32.235.072 von spaceistheplace am 01.11.07 16:17:46

hallo space,

mit Verwunderung habe ich gelesen, dass du dich mit dem Gedanken trägst auszusteigen. Schade. Srcl ist eine Ausnahmeaktie, so ruhig, so stetig - Marktnische, Platz um zu wachsen.
Nur um weniger verschiedene Titel zu haben?
So sprunghaft kenne ich dich eigentlich nicht.

gruß clearasil

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.578.783 von clearasil am 27.11.07 10:18:21

ja, bis Ende 2008 werde ich SRCL wohl verkaufen, da ich die Aktie eher nicht als ASS-Vehikel sehe. Aktuell jedenfalls keinerlei Ambitionen klar Schiff zu machen.
Ab 2009 werde ich mich eh mehr oder minder nicht mehr groß und die Börse kümmern und auch nicht mehr groß nach den Kursen schauen.
Ich mache aktuell viel zu viel hier. Manchmal kommen wichtigere Dinge gar zu kurz. das muss und wird sich ändern.

Gruss space

[spaceistheplace]

Stericycle Announces Inclusion in NASDAQ-100 Index(R)

Last update: 8:07 p.m. EST Dec. 14, 2007
PrintPrint EmailE-mail Subscribe to RSSRSS DisableDisable Live Quotes
LAKE FOREST, Ill., Dec 14, 2007 (BUSINESS WIRE) -- Stericycle, Inc. today announced that effective December 24, 2007 it has been selected by NASDAQ(R) for inclusion in its NASDAQ-100 Index(R). This index consists of 100 of the largest domestic and international non-financial securities listed on The Nasdaq Stock Market(R) based on market capitalization.
"We are very pleased to receive this recognition of our growth from NASDAQ(R)," said Mark Miller, Stericycle CEO, "as it represents a major milestone in our company's commitment to helping our customers protect their employees and reduce risk."
Only two companies, Dell and Starbucks , in the current NASDAQ-100(R) had positive year over year market value growth from IPO to 11 years post IPO. SRCL will be the third company in the NASDAQ-100(R) to achieve 11 years of sustained growth since going public in 1996.
NASDAQ(R), NASDAQ-100 Index(R) and The NASDAQ Stock Market(R) are registered trademarks of The Nasdaq Stock Market, Inc.

[clearasil]

Antwort auf Beitrag Nr.: 32.780.462 von spaceistheplace am 16.12.07 10:38:49

S&P on SRCL 10-Jan-08 11:39 am From a research report dated Jan 9th:

Our risk assessment reflects our view that the
regulated medical waste industry is relatively
recession resistant, debt levels are adequate, and
cash flow generation is sufficient. However, we
have some concerns regarding corporate
governance, including stock-based incentive
plans being adopted without shareholder
approval.

We have a buy recommendation on the shares
based on favorable domestic and international
trends in the medical waste business, as well
as the stock's low beta and our view of the
company's highly consistent operating model
with solid cash flow generation.

Risks to our recommendation and target price
include potential new competitors, significant
changes in environmental regulations for medical
waste disposal, a further significant rise in
fuel and energy costs, and problems integrating
acquisitions.

We attribute the stock's above five-year average
and peer forward P/E of 35X our 2008 EPS
estimate to the company's broad medical services
network, expanding market reach, and
accretive acquisition strategy. Using historical
and projected price-to-sales, P/E to three-year
EPS growth (PEG) and price to EBITDA ratios,
we derive a relative valuation of $64. Based on
our DCF analysis, assuming 4% terminal growth
and an 8% cost of capital, our intrinsic valuation
estimate is $71. Blending these metrics, we
arrive at our 12-month target price of $67.

[spaceistheplace]

Antwort auf Beitrag Nr.: 33.197.267 von clearasil am 29.01.08 00:56:43

Hallo c., danke für den Bericht. SRCL hält sich jedenfalls blendend in diesen stürmischen zeiten. Bewertung ist zwar sportlich, aber bisher auch keinerlei Enttäuschungen.

Gruss space

[spaceistheplace]

Guten Morgen miteinander,

will mich mal melden, denn ich habe Euch was mitzuteilen:

Ich werde mich ab sofort aus WO und aus dem ganzen Börsengeschehen mehr oder minder zurückziehen. Ich habe mir das schon länger überlegt und bin jetzt über Ostern zu diesem Schluss gekommen.

Ich habe gestern fast komplett meinen Aktienbestand verkloppt. Ich habe mit meiner Bank, bei der ich einen Kredit über unser Haus laufen habe, ein große Sondertilgung vereinbart und werde diese in diesen Tagen durchführen. Da fließt das Geld hinein. Lieber meinen Kredit tilgen bzw. abbezahlen als auf im Endeffekt höhere Renditen am Markt spekulieren. Das kann böse in die Hose gehen bzw. ich denke, das eben die Renditen an den Märkten in den nächsten jahren nicht zum Himmel wachsen. Nummer Sicher, fertig...

Ein sehr kleiner Rest ist noch nicht über die Spekufrist (sind aber eh keine großen Gewinne drauf), warte diese aber ab. Bis Ende des Jahres wird dann der Rest des Kredites abbezahlt.

Zudem bin ich auch zum Schluss gekommen, hier bei WO meine Aktivitäten einzustellen. Ich hatte ja schon öfters geschrieben, dass ich zu viel Zeit aufwende und dann doch immer wieder in die gleiche Schiene verfallen bin, einfach zu viel Zeit dafür aufzuwenden, oft auch einfach zu verbissen war, was ich als nicht gut empfinde. Daher werde ich jetzt komplett aufhören und mich auch abmelden, sonst wird das wieder nix.

Also macht es gut, haltet den Thread auch ohne mich als Threadgrünmder warm…
Liebe Grüße an alle
space

[spaceistheplace2]

Hallo zusammen,

I'm back on board bei WO zwar unter einem anderen Usernamen, aber immer noch der Gleiche mit den gleichen Favoriten. Ich wüsste auch nicht, was sich grundsätzlich an diesen Unternehmen groß geändert haben sollte, Krise hin oder her....

Ich poste hier, damit der Thread nicht einschläft und werde mich gegebenfalls einbringen, wenn ich es für notwendig erachte. Die "Versorgung" mit news hier werde ich aber so nicht mehr wie gewohnt durchführen, allein schon wegen Zeitmangels.
Vornehmlich werde ich aber im Gewinnerthread " Gewinnerbranchen der Jahre 2006 bis 2040" posten.

Gruss space

[spaceistheplace]

Hallo,

so, ich habe mir jetzt wieder den alten Namen freischalten lassen von WO, bin also wieder wie gewohnt unter dem namen "spaceistheplace" on board.

Gruß
space

[spaceistheplace]

SRCL-Zahlen:

http://www.finanznachrichten.de/nachrichten-2008-10/artikel-…

[Fatalis]

Hallo,

habe mir mal die Geschäftsberichte angeschaut. Konnte aber auf Anhieb keine Aussagen zur weiteren Geschäftsentwicklung finden.
Die Aktie scheint derzeit sehr gut bewertet zu sein und hat in den letzten Wochen wohl auch ein bisschen gelitten.

Aus meiner Sicht ein geeigneter Zeitpunkt um einzusteigen, da ich am restlichem Markt derzeit mehr Risiken als Chancen sehe.

Und noch eine doofe Frage: Soll ich die Aktie in Frankfurt oder dierekt im Amiland kaufen?

[clearasil]

Antwort auf Beitrag Nr.: 35.768.705 von Fatalis am 30.10.08 19:57:24

hi fatalis, jemand , der sich für srcl interessiert. Ein Wunder!!!

aktuelles zur Geschäftsentwicklung findest du hier

http://seekingalpha.com/article/101643-stericycle-inc-q3-200…

Aktie gut bezahlt, aber überragende relative Stärke gegenüber Gesamtmarkt.
Dürfte vorerst bei einer volatilen Setwärtsbewegung bleiben.

Kannst dir beschlimmt viele schlechtere Teile kaufen.

Frankfurt ist o.k. , da nasdaq 100, normale spreads.

viel Glück mit dieser besonderen Aktie

bin seit 08/07 investiert und habe es nicht bereut

gruß clearasil

[clearasil]

alle infos auch hier

http://finance.yahoo.com/q?s=SRCL

[clearasil]

Stericycle (SRCL). Stericycle cleans up after the medical industry, disposing of hazardous or infectious medical waste for doctors, dentists, and drug makers. Its expertise navigating the complex web of public safety rules, paperwork, and other services makes it vital to customers no matter how the rest of the economy is doing. Its already sizable 10 percent chunk of a fragmented $10 billion market is expected to grow as the firm expands overseas as it has in the United Kingdom and South America and through acquisitions (it has made 140 since 1993).[b] Earnings look steady, growing at a 17 percent annual rate over the past five years, and analysts predict similar gains for at least the next two.[/b] Oppenheimer analysts note the firm "has perpetually grown its core med-waste business in the high single digits organically" and expects more of the same despite the "daunting economic outlook."

[Fatalis]

Vielen Dank!

Werde mir mal mit meinen bescheidenen Möglichkeiten einige Aktien beiseite legen. Auf jedenfall spannender wie ein Tagesgeldkonto aber dabei nicht viel mehr Risiko.

Die Zahlen sind super und der Ausblick ist auch nicht schlecht. Das das Wachstum durch zukäufe bei diesem Unternehmen funktioniert, sieht man ja deutlich an der Vergangenheit.

Werde hier auf jedem Fall am Ball bleiben.

[spaceistheplace]

Hallo, Ihr 2 SRCL-Fans.

Muss mich auch mal melden, da ich schon investiert war bis vor fast nem jahr.

Gewiss ein toller Langfristchart, allein die Bewertung ist mir zu hoch.
Der kleinste Einbruch kann ne halbierung des Kurses bedeuten. ist ein tanz auf dem Vuilkan, um es überspitzt zu formulieren.

Auf jedenfall spannender wie ein Tagesgeldkonto aber dabei nicht viel mehr Risiko.

dass Du da Du Dich mal nicht täuschst...Aktien sind immer mit Risiko verbunden. ich habe schon viele Aktien erlebt, die hoch bewertet waren und das über Jahre durchhilelten, bis dann aber mal ein Einbruch kam.
Der aktuelle Fall, wie jeder weiss, ist Starbucks. Okay, die erwischte es schlimm, SRCL ist da in einer "sichereren" Branche unterwegs, aber im Hinterkopf sollte man das immer behalten, dass auch mal ein Wachstumseinbruch kommen kann und dann wirds bitter, denn die Entwicklung wir schon jetzt für 2-3 Jahre fortgeschrieben.

Gruss space

[Fatalis]

Ich muss sowieso auf einen kleinen Rücksetzer der Aktie warten. Bin der Überzeugung, dass der Markt insgesamt noch mal einen Rutsch nach unten macht. Die Erholung ging viel zu schnell.

Da ich gestern fast mein ganzes Depot aufgelöst haben (großteil am Freitag letzter Woche gekauft) möchte ich den Gewinn aus dieser Aktion hier etwas konservativer anlegen.

So richtig kann ich kein echtes Risiko bei dieser Aktie sehen bis auf:

- Devisenschwankungen
- geringes organisches Wachstum
- Wachstum nur mit Neuaquisitionen

So hab ich es aus den Berichten gelesen. Das heißt der Worstcase wäre, wenn SRCL die Liquidität für Neuaquisen ausgeht bzw. die Neuaquise nicht den geplanten Ertrag erwirtschaftet.

Gruß Fatalis

[wptrading]

sind gerade charttechnisch ausgebrochen aus einem Doppelboden. Kaufpunkt war 58,04.


könnte jetzt richtig abgehen, bin am überlegen ob ich die ordere.


befinden sich auf meiner WL (wptrading.blogspot.com)

[Fatalis]

Nach meiner Analyse ist "abgehen" eventuell das falsche Wort für diese Aktie. Ich denke aber, dass die Aktie ihren langfristigen Aufwärtstrend fortsetzen wird. Ich werde auf jeden Fall diese Woche noch abwarten. Politisch passiert momentan viel und diesen Faktor möchte ich für mich noch abhaken und sehen wie die Börsen reagieren.

Danach werde ich entscheiden. Fundamental ist diese Aktie aus verschiedenen Blickwinkeln her sehr interessant.

Gruß
Fatalis

[spaceistheplace]

Stericycle to replace Anheuser-Busch on S&P 500
By Wallace Witkowski
Last update: 7:00 p.m. EST Nov. 17, 2008
SAN FRANCISCO (MarketWatch) -- Standard & Poor's said late Monday that Stericycle Inc. (SRCL:
Stericycle Inc
News, chart, profile, more
Last: 58.87+0.86+1.48%
4:00pm 11/17/2008
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
SRCL 58.87, +0.86, +1.5%) will replace Anheuser-Busch Cos. (BUD:
BUD
News, chart, profile, more
Last:

Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
BUD, , ) in the S&P 500. Also, Life Technologies Corp., which is a merger of Invitrogen Corp. (IVGN:
IVGN
News, chart, profile, more
Last:

Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
IVGN, , ) and Applied Biosystems Inc. (ABI:
ABI
News, chart, profile, more
Last:

Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
ABI, , ) expected to close on Friday, will replace Applied Biosystems on the S&P 500. Life Technologies will be listed on the Nasdaq under the ticker "LIFE." End of Story

[clearasil]

Antwort auf Beitrag Nr.: 35.990.230 von spaceistheplace am 18.11.08 14:00:48

Stericycle to replace Anheuser-Busch on S&P 500

danke space , das wäre die Erklärung für die doch ausserordentliche rsi in der letzten Zeit.

[Fatalis]

Seit knapp 10 Tagen bin ich stolzer Besitzer dieser tollen Aktie.
Mit dem Verlauf bin ich sehr zufrieden und die Nachricht heute sollte längerfristig auch noch ein bisschen Schwung geben.

Die Firma ist erstaunlich ereignisarm und bringt jeden Tag ein kleines und bescheidenes Plus. Seit ich die Aktie am 28.10. in meine Watchlist aufgenommen habe ist der Wert um 18 % gestiegen.
Ich habe keinen anderen Wert im Depot bei dem dies per Stand heute ähnlich ist.

Ich denke der Wert wird sich schön kontinuierlich weiter entwickeln.
Aber von deutlichen Kurssprüngen denke kann man glaub ich nicht ausgehen.

Allen Mitinvestierten drücke ich weiterhin die Daumen.

[clearasil]

viele interessante facts über srcl

Stericycle: A Healthcare Diamond in the Industrial Rough
by: Bullish Bankers December 08, 2008 | about stocks: SRCL
Bullish Bankers
Add to Your WatchlistAbout this author:
Bio & more articles
Visit: Bullish Bankers
Become a Contributor Submit an Article Font Size: PrintEmail One of the weakest sectors in this current market environment is most clearly the industrial sector. It is a sector that benefits from economic prosperity and booming markets to fuel growth. As rational investors know the key to eliminating unsystematic risk is diversification, and that is why it is key to still have an industrial stock in your portfolio. There is a industrial stock that benefits from one of the most stable sectors in this environment. That slowing markets and a global infrastructure slowdown can’t hold this company back from prospering. I’m talking about Stericycle (SRCL): a healthcare company hidden deep within the industrial sector.


Stericycle is a medical waste services company that provides bio-hazardous medical waste disposal and infection control services for medical care facilities. They serve over 400,000 customers including: hospitals, blood banks, pharmaceutical manufacturers, out-patient clinics, acute care facilities as well as many others. They also operate not only in the United States but in Canada, Mexico, Argentina, Ireland and the United Kingdom. They operate within four business segments:

Domestic Medical Waste Management: Collection and transportation comprise this segment. Collection involves providing clients with reusable leak and puncture resistant containers for collecting hazardous bio-waste. Transportation involves collection of provided containers for proper disposal.
Domestic Pharmaceutical Returns: Stericycle picks up or receives shipments of excess pharmaceutical drugs from retail pharmacies in the United States.
Foreign Medical Waste Management: Stericycle has set up national waste management facilities in foreign countries where they take the bio-waste and dispose of it.
Foreign Equipment and Technical Licensing: This segment is in charge of training and licensing in accordance with foreign government regulations.
Market Stability

Regardless of what is going on in the economy, there will continue to be medical waste that must be disposed. It is inevitable that hospitals will continue to run, and thus bio-waste will need to be managed. Aside from the obvious, Stericycle also has a very stable contract base. They engage in fixed fee arrangements, which account for nearly half of the revenue base. They also engage in lengthy contracts, with the domestic contracts averaging 3-5 years and the international contracts averaging 3-15 years with the lengthier ones being in the United Kingdom. As if that is not enough stability, Stericycle maintain a 95% revenue retention rate. So you may be wondering how oil impacts their business since they are in the transportation business. Their contracts generally include what is called pass-through-price increase provisions which is their “hedge” against high oil prices.

So based on what they do, it is evident that they operate in a stable industry. That alone makes me love them in this type of market. But just to drive the point home here are a few more reasons as to why Stericycle could be your ultimate hedge in your portfolio to the recession.

Strong Growth Potential

There is safe growth within a necessary product base when looking at Stericycle's business. However, Stericycle is also beginning to penetrate emerging markets. This is perfect because while the emerging markets are currently down, Stericycle is taking advantage of the situation and is poising itself for immense growth potential. Stericycle also has an initiative called Steri-Safe, which provides low-cost, high quality products and services for poorly financed companies.

Along with this initiative, they also maintain a diverse customer base. Their largest customer accounts for less than 2% of revenues. They have also proven themselves to be great integrators, successfully completing 140 acquisitions since 1993. Their acquisition pipeline is also expanding. Currently, European valuations are much more attractive than domestic ones, and Stericycle is looking to take advantage of this going forward. There is still potential with the way the economy is deteriorating, and domestic companies will become available at fire sale prices. This could set Stericycle up for a huge value-added event in the near future.

Favorable Medical Trends

When you operate in a highly regulated industry, there tend to be some advantages within niches of the industry. In the case of Stericycle, the main advantage is the safe demand of the industry since it is a necessity. One of the current trends that I see continuing into the future is the high demand for their services. This demand allows Stericycle to maintain strong pricing power. Now you may be wondering why other companies are not trying to penetrate into this industry. Because the industry is very highly regulated, it is very hard and expensive to get this type of business going. Stericycle alone is regulated by the EPA, DEA, FDA, OSHA and DOT. Thus I feel that Stericycle will be able to maintain strong volumes and the competition will stay limited.

Summary

While Industrials is a very touchy sector right now, this opportunity could be your ultimate play within the sector. They operate in a recession proof industry and they have clearly proven that they know how to grow their business. Along with that, government regulation keeps potential competitors out and allows Stericycle to maintain their pricing power. So if you are looking to position yourself as the economy continues to spiral downwards, then I highly recommend you do it through investing in Stericycle!